270 related articles for article (PubMed ID: 21145960)
1. Performance evaluation of PAMAM dendrimer based simvastatin formulations.
Kulhari H; Pooja D; Prajapati SK; Chauhan AS
Int J Pharm; 2011 Feb; 405(1-2):203-9. PubMed ID: 21145960
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia.
Kulhari H; Kulhari DP; Prajapati SK; Chauhan AS
Mol Pharm; 2013 Jul; 10(7):2528-33. PubMed ID: 23692066
[TBL] [Abstract][Full Text] [Related]
3. Poly (amidoamine) dendrimer-mediated hybrid formulation for combination therapy of ramipril and hydrochlorothiazide.
Singh MK; Pooja D; Kulhari H; Jain SK; Sistla R; Chauhan AS
Eur J Pharm Sci; 2017 Jan; 96():84-92. PubMed ID: 27614111
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug.
Ma M; Cheng Y; Xu Z; Xu P; Qu H; Fang Y; Xu T; Wen L
Eur J Med Chem; 2007 Jan; 42(1):93-8. PubMed ID: 17095123
[TBL] [Abstract][Full Text] [Related]
5. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam.
Prajapati RN; Tekade RK; Gupta U; Gajbhiye V; Jain NK
Mol Pharm; 2009; 6(3):940-50. PubMed ID: 19231841
[TBL] [Abstract][Full Text] [Related]
6. Thermosensitive properties of poly(amidoamine) dendrimers with peripheral phenylalanine residues.
Tono Y; Kojima C; Haba Y; Takahashi T; Harada A; Yagi S; Kono K
Langmuir; 2006 May; 22(11):4920-2. PubMed ID: 16700575
[TBL] [Abstract][Full Text] [Related]
7. Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies.
Cheng Y; Li M; Xu T
Eur J Med Chem; 2008 Aug; 43(8):1791-5. PubMed ID: 18215444
[TBL] [Abstract][Full Text] [Related]
8. Interaction between PAMAM-NH₂ G4 dendrimer and 5-fluorouracil in aqueous solution.
Buczkowski A; Sekowski S; Grala A; Palecz D; Milowska K; Urbaniak P; Gabryelak T; Piekarski H; Palecz B
Int J Pharm; 2011 Apr; 408(1-2):266-70. PubMed ID: 21335079
[TBL] [Abstract][Full Text] [Related]
9. G5 PAMAM dendrimer versus liposome: a comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin.
Qi R; Zhang H; Xu L; Shen W; Chen C; Wang C; Cao Y; Wang Y; van Dongen MA; He B; Wang S; Liu G; Banaszak Holl MM; Zhang Q
Nanomedicine; 2015 Jul; 11(5):1141-51. PubMed ID: 25791813
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins.
Devarakonda B; Hill RA; Liebenberg W; Brits M; de Villiers MM
Int J Pharm; 2005 Nov; 304(1-2):193-209. PubMed ID: 16198076
[TBL] [Abstract][Full Text] [Related]
11. Solubility of nicotinic acid in polyamidoamine dendrimer solutions.
Yiyun C; Tongwen X
Eur J Med Chem; 2005 Dec; 40(12):1384-9. PubMed ID: 16226352
[TBL] [Abstract][Full Text] [Related]
12. Inclusion complexes of isoflavones with two commercially available dendrimers: Solubility, stability, structures, release behaviors, cytotoxicity, and anti-oxidant activities.
Zhao C; Wang Y; Su Y; Zhang H; Ding L; Yan X; Zhao D; Shao N; Ye X; Cheng Y
Int J Pharm; 2011 Dec; 421(2):301-9. PubMed ID: 22001794
[TBL] [Abstract][Full Text] [Related]
13. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
14. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells.
Gupta U; Dwivedi SK; Bid HK; Konwar R; Jain NK
Int J Pharm; 2010 Jun; 393(1-2):185-96. PubMed ID: 20382210
[TBL] [Abstract][Full Text] [Related]
15. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers.
Yiyun C; Tongwen X
Eur J Med Chem; 2005 Nov; 40(11):1188-92. PubMed ID: 16153746
[TBL] [Abstract][Full Text] [Related]
16. New insights into the interactions between dendrimers and surfactants: 2. Design of new drug formulations based on dendrimer-surfactant aggregates.
Cheng Y; Wu Q; Li Y; Hu J; Xu T
J Phys Chem B; 2009 Jun; 113(24):8339-46. PubMed ID: 19469491
[TBL] [Abstract][Full Text] [Related]
17. Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation.
Kulhari H; Pooja D; Singh MK; Chauhan AS
Drug Dev Ind Pharm; 2015 Feb; 41(2):232-8. PubMed ID: 24237325
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel dendrimers having aspartate grafts and their ability to enhance the aqueous solubility of model drugs.
Ouyang L; Ma L; Jiang B; Li Y; He D; Guo L
Eur J Med Chem; 2010 Jun; 45(6):2705-11. PubMed ID: 20171762
[TBL] [Abstract][Full Text] [Related]
19. Host-guest chemistry of dendrimer-drug complexes. 2. Effects of molecular properties of guests and surface functionalities of dendrimers.
Hu J; Cheng Y; Wu Q; Zhao L; Xu T
J Phys Chem B; 2009 Aug; 113(31):10650-9. PubMed ID: 19603764
[TBL] [Abstract][Full Text] [Related]
20. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
